Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Malick Islam

Internal Medicine Lewes, DE Medical Doctor

NPI 1265663124 CMS profile 2433136

34453 King Street Row, Ste 2, Lewes, DE 19958

Open in the dashboard

General payments

$11,264

267 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Malick Islam of Lewes, DE is reported in the CMS Open Payments database as having received $11,264 across 267 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $183 2
2024 General $613 18
2023 General $1,635 34
2022 General $3,534 60
2021 General $1,086 40
2020 General $2,249 53
2019 General $1,965 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Malick Islam
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Malick Islam were reported at $183. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Malick Islam Internal Medicine median Middle half National median
2019 $1,965 $159 $48–$570 $163
2020 $2,249 $119 $33–$402 $114
2021 $1,086 $135 $37–$521 $132
2022 $3,534 $141 $42–$496 $149
2023 $1,635 $149 $45–$519 $160
2024 $613 $154 $47–$537 $164
2025 $183 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $4,256 77 payments
  2. Medtronic Vascular, Inc. $2,221 50 payments
  3. Boston Scientific Corporation $1,275 19 payments
  4. Medtronic, Inc. $949 37 payments
  5. Biosense Webster, Inc. $620 26 payments
  6. Cardiovascular Systems Inc. $460 8 payments
  7. Cook Medical LLC $283 4 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $245 2 payments
  9. Novartis Pharmaceuticals Corporation $126 4 payments
  10. Amgen Inc. $124 7 payments
  11. Other $706 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,563 254 payments
  2. Travel and Lodging $2,568 9 payments
  3. Consulting Fee $1,000 1 payment
  4. Education $82 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50 1 payment
Products named General payments · program years 2019–2025
  1. AVEIR $2,220 11 payments
  2. WATCHMAN Access System $1,058 7 payments
  3. Performa $721 5 payments
  4. Carto 3 $585 25 payments
  5. Coronary Orbital Atherectomy System $439 7 payments
  6. Micra Pacemakers $434 13 payments
  7. Agilis NxT EP Introducer $324 5 payments
  8. MICRA Pacemakers $292 10 payments
  9. Confirm Rx $291 9 payments
  10. Reveal LINQ $276 8 payments
  11. Other $5,112 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

106

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$33,777

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

23.6%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 25 $31,678
Metoprolol Succinate Generic 44 $1,032
Bisoprolol Fumarate Generic 20 $670
Amiodarone Hcl Generic 17 $397

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$96,028

Medicare's payments for the services billed

Medicare patients

807

Average age 77

Services billed

1,841

400 women, 407 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 60%
Ischemic heart disease 58%
Heart failure 55%
Arthritis 51%
Diabetes 49%
Chronic kidney disease 43%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record